EarningsQ2 2026 Earnings Report
MX:ARGXN Q2 2026 EPS Results
Actual EPS$131.48
Consensus EPS$113.92
Beat/MissBeat by +$17.57
One Year Ago EPS$67.18
MX:ARGXN Q2 2026 Revenue Results
Actual Revenue$50.58B
Expected Revenue$26.02B
Beat/MissBeat by +$24.56B
YoY Revenue Growth+60.67%
Earnings Announcement Details
QuarterQ2 2026
Date07/23/2026
TimeBefore Open
Conference CallThursday, July 23, 2026
MX:ARGXN Upcoming Earnings
Argenx Se's next earnings date is estimated for October 22, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:ARGXN Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong commercial and financial momentum — highlighted by $1.5B in Q2 product sales (+60% YoY), robust operating profit (+146% YoY), a $5.2B cash balance, regulatory wins (seronegative gMG approval) and multiple near-term clinical readouts (myositis, MMN). Offsetting risks include higher operating spending ($903M R&D+SG&A), some one-time contributions in Japan sales, unresolved clinical read-throughs (DGF) and inherent trial complexity in CIDP and myositis subsets plus payer and habit barriers for earlier CIDP adoption. Overall, the positives — substantial revenue/profit growth, strong cash generation, label expansion and a deepening pipeline with imminent catalysts — outweigh the manageable near-term risks and uncertainties.Company Guidance
Record Quarterly Revenue Growth
Product net sales of $1.5B in Q2 FY2026, up 60% year-over-year and 17% quarter-over-quarter; U.S. sales were $1.3B (U.S. market +15% QoQ), Japan $102M, Rest of World $136M, China $5M.
Strong Profitability and Cash Position
Operating profit of $494M in Q2, an increase of 146% year-over-year; cash, cash equivalents and current financial assets totaled $5.2B, up more than $744M from the beginning of the year.
Sustained Growth Momentum
18th consecutive quarter of growth driven by expanding patient uptake and commercialization execution; management expects continued shape of growth similar to prior years after expected Q1 seasonality.
VYVGART Commercial Leadership and Market Expansion
Approval for seronegative generalized MG makes VYVGART first and only treatment approved across all gMG serotypes, expanding MG addressable market by ~11,000 patients; payer policies cover ~55% of U.S. commercial lives within ~10 weeks, with many plans removing serology testing requirements.
Prefilled Syringe Driving New Patient Adoption
Prefilled syringe (PFS) continues to broaden adoption; ~80% of PFS patients in the U.S. in Q2 were new to VYVGART (launch-to-date ~70%), supporting earlier line use and higher adherence.
Near-Term Clinical Catalysts
Two registrational readouts expected before year-end: myositis readout in Q3 (IMNM and DM subsets analyzed independently) and MMN registrational readout later this year; these can materially expand labeled indications.
Empasiprubart and FcRn Pipeline Progress
Empasiprubart showed efficacy, durability and safety in Phase II ARDA (notable sustained grip-strength improvement); ARGX-213 is Phase III-ready and ARGX-124 is progressing from Phase I toward late-stage development by year-end; goal to advance 5 late-stage molecules by 2030.
ARGX-121 IgA Sweeper Early Efficacy
Phase I data for ARGX-121 demonstrated ~90% IgA reduction within days after a single dose with reductions maintained through day 28, supporting rapid move into IgAN Phase II development.
Commercial Execution in CIDP
CIDP adoption growing with data-driven messaging: Phase IV switch study showed 87% of patients on IVIg switched successfully to VYVGART; evidence generation supports treating earlier and switching from IVIg.
MX:ARGXN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed